Study of YG1699 in diabetic kidney disease patients
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine, YG1699, in people with diabetic kidney disease, including those on dialysis. It aims to see how the drug works in your body and how it affects your blood sugar.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have diabetes (type 1 or type 2) with kidney disease.
- Your fasting blood sugar is below 11.1 mmol/L and your diabetes medicine has been stable for at least 2 weeks.
- You have not taken SGLT2 inhibitor drugs (like empagliflozin) in the past month.
- You have not had more than 2 low blood sugar episodes in the past month, and no history of diabetic ketoacidosis.
- You are not pregnant or breastfeeding, and have no active infections or untreated tumors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called LC-Z300-01 to see if it can reduce protein in the urine of people with type 2 diabetes and diabetic kidney disease. If you have diabetic kidney disease and are already on standard kidney-protective medications, this trial may offer a potential new treatment option.
This trial tests whether a new drug, HTD1801, can protect or improve kidney function in people with type 2 diabetes and chronic kidney disease. It may help slow kidney damage and reduce protein in urine.
This study tests a new medication (DWP16001) for people with type 2 diabetes and moderate kidney disease. It aims to see if the drug helps protect kidney health and manage blood sugar.
This study tests a new medicine called AP303 for people with type 2 diabetes and chronic kidney disease. The goal is to see if it is safe and how the body processes it. If you have diabetes and your kidneys are not working as well as they used to, this trial might help find new treatment options.
This Phase 2 study tests whether adding NAD can improve kidney health in people with diabetes-related kidney disease. It is designed for people with certain urine lab results showing kidney stress, while keeping blood sugar and safety limits within range.
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
Hear when a new Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.